Marc R. Arnone

Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors

Tara Rheault, John Stellwagen, George M. Adjabeng et al. · ACS Medicinal Chemistry Letters · 2013 · 253 citations · Full text

B-raf-driven Tumors, Antitumor Activity, Hyperactive Signaling +16

Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions

Alastair J. King, Marc R. Arnone, Maureen R. Bleam et al. · PLoS ONE · 2013 · 212 citations · Full text

Dermatology, Tumor Biology, Signaling Pathway +17

A biochemical rationale for the anticancer effects of Hsp90 inhibitors: Slow, tight binding inhibition by geldanamycin and its analogues

Lata T. Gooljarsingh, Christine Fernandes, Kang Yan et al. · Proceedings of the National Academy of Sciences · 2006 · 118 citations · Full text

Biochemical Rationale, Drug Target, Drug Resistance +19

Synthesis and Biological Evaluation of 1-Aryl-4,5-dihydro-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-one Inhibitors of Cyclin-Dependent Kinases

Jay A. Markwalder, Marc R. Arnone, Pamela A. Benfield et al. · Journal of Medicinal Chemistry · 2004 · 100 citations · Full text

High-throughput Screening Strategy, Drug Target, Molecular Biology +18

Putative identification of functional interactions between DNA intercalating agents and topoisomerase II using the V79 in vitro micronucleus assay

Ronald D. Snyder, Marc R. Arnone · Mutation research. Fundamental and molecular mechanisms of mutagenesis · 2002 · 93 citations

Chromatin, Biochemistry, Functional Interactions +8